The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat ...

Edwards Lifesciences Corporation ( NYSE: EW) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - ...

This week’s Bulls N’ Bears ASX Runner of the Week is… Redstone Resources, which announced a biblically deep drill hole to ...

Anteris Technologies Global Corp.’s AVR share price has surged by 12.25%, which has investors questioning if this is right time to sell.

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic stenosis (AS), a valvular heart condition that can be ...

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

Oral hormone therapy may benefit heart health in menopausal women. A new analysis of data from the Women's Health Initiative found that estrogen-based oral hormone therapy had a long-term beneficial ...

The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.